Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors
摘要:
The HGF-c-Met signaling axis is an important paracrine mediator of epithelial-mesenchymal cell interactions involving the regulation of multiple cellular activities including cell motility, mitogenesis, morphogenesis, and angiogenesis. Dysregulation of c-Met signaling (e. g., overexpression or increased activation) is associated with the development of a wide range of tumor types; thus, inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of a 2-arylaminopyrimidine scaffold led to a series of potent c-Met inhibitors bearing a C4-2-amino-N-methylbenzamide group. Specifically, a series of C2-benzazepinone analogs demonstrated potent inhibition of c-Met in enzymatic and cellular assays. Kinase selectivity could be tuned by varying the nature of the alkyl group on the benzazepinone nitrogen. (C) 2010 Elsevier Ltd. All rights reserved.
The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
The present invention relates to a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein R
1
, R
2
, R
3
, R
11
, R
12
, R
13
, Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists
作者:Takashi Mizutani、Tsuyoshi Nagase、Sayaka Ito、Yasuhisa Miyamoto、Takeshi Tanaka、Norihiro Takenaga、Shigeru Tokita、Nagaaki Sato
DOI:10.1016/j.bmcl.2008.10.034
日期:2008.12
Novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives were identified as potent human H(3) receptor inverse agonists. After systematic modification of lead 5a, the potent and selective analog 5r was identified. Elimination of hERG K(+) channel and human alpha(1A)-adrenoceptor activities is the main focus of the present study.
The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I)
wherein A
1
, A
2
,
R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.
[EN] NITROGEN CONTAINING HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES CONTENANT DE L'AZOTE
申请人:HOFFMANN LA ROCHE
公开号:WO2011154327A1
公开(公告)日:2011-12-15
The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, (a), R1, R2, R3, R4, R5 and R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.